Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2793-2796

  Schaad, H J ^a,d   Petty, B G ^a,c   Grasela, D M ^b   Christofalo, B ^b   Raymond, R ^b   Stewart, M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; STAVUDINE;

ABDOMINAL CRAMP; ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIGESTION; KIDNEY CLEARANCE; LIVER CIRRHOSIS; LIVER DISEASE; MALE; NOTE; PRIORITY JOURNAL;

EID: 0030817869     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2793     Document Type: Note

References (14)

1. Albers, I., H. Hartmann, J. Bircher, and W. Creutzfeldt. 1989. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand. J. Gastroenterol. 24:269-276.
2. Caregaro, L., F. Menon, P. Angeli, P. Amodio, C. Merkel, A. Bertoluzzi, F. Alberino, and A. Gatta. 1994. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch. Intern. Med. 154:201-205.
3. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
4. Dudley, M. N., K. K. Graham, S. Kaul, S. Geletko, L. Dunkle, M. Brown, and K. Mayer. 1992. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:480-485.
5. Farmen, R. H., J. F. Muniak, and K. A. Pittman. 1987. Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug. Inf. J. 21:141-152.
6. Hitchcock, M. J. M. 1991. 2′,3′-Didehydro-2′,3′-dideoxythymidine (d4T), an anti-HIV agent. Antivir. Chem. Chemother. 2:125-132.
7. Janiszewski, S., D. E. Mulnava, S. Kaul, K. A. Dandekar, and R. H. Barbhaiya. 1992. High-performance liquid chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine. J. Chromatogr. 577:151-156.
8. Lea, A. P., and D. Faulds. 1996. Stavudine: a review of its pharmacodynamics and pharmacokinetic properties and clinical potential in HIV infection. Drugs 51:846-864.
9. Locke, C. S. 1984. An exact confidence interval from untransformed data for the ratio of two formulation means. J. Pharmacokinet. Biopharm. 12:649-655.
10. Murray, H. W., K. E. Squires, W. Weiss, S. Sledy, H. S. Sacks, J. Hassett, A. Cross, R. E. Anderson, and L. M. Dunkle. 1995. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J. Infect. Dis. 171(Suppl. 2):S123-S130.
11. Niederberger, M., and R. W. Schrier. 1992. Pathogenesis of sodium and water retention in liver disease. Prog. Liver Dis. 10:329-347.
12. Pugh, R. N. H., I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:646-648.
13. Riegelmann, S., and P. Collier. 1980. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm. 8:509-534.
14. Skowron, G. 1995. Biologic effects and safety of stavudine: overview of Phase I and II clinical trials. J. Infect. Dis. 171(Suppl. 2):S113-S117.